CERo Therapeutics
CERO
CERO was delisted on the 30th of October, 2025.
46 hedge funds and large institutions have $139M invested in CERo Therapeutics in 2022 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 3 closing their positions.
333% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 3
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
34% more capital invested
Capital invested by funds: $104M → $139M (+$35.1M)
28% more funds holding
Funds holding: 36 → 46 (+10)
18.57% more ownership
Funds ownership: 57.16% → 75.72% (+19%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$5.97M |
| 2 |
HIM
HGC Investment Management
Toronto,
Ontario, Canada
|
+$4.97M |
| 3 |
LA
Linden Advisors
New York
|
+$4.97M |
| 4 |
MI
MMCAP International
Grand Cayman,
Cayman Islands
|
+$4.97M |
| 5 |
CCM
Context Capital Management
Lajolla,
California
|
+$3.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCM
Oaktree Capital Management
Los Angeles,
California
|
-$1.98M |
| 2 |
CL
CSS LLC
Chicago,
Illinois
|
-$418K |
| 3 |
TI
Telemetry Investments
New York
|
-$304K |
| 4 |
PCM
Pinz Capital Management
New York
|
-$72K |
| 5 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$59.7K |
CERO Hedge Fund Activity: Q1 2022 in Review
46 of the 6,361 institutional investors tracked by Wall St. Rank reported a position in CERo Therapeutics (CERO) for Q1 2022, worth a combined $139M — up 34% from $104M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new CERO positions and 3 closed out — a net gain of 10 holders — while 8 added to existing stakes and 4 trimmed.
The largest buyer was Periscope Capital, opening a new position worth an estimated $5.97M. The largest seller was Oaktree Capital Management, exiting entirely with an estimated $1.98M sold.
- 46 institutional investors held CERo Therapeutics (CERO) as of Q1 2022, up from 36 in Q4 2021.
- Funds reported $139M of CERo Therapeutics stock for Q1 2022, up 34% quarter-over-quarter.
- 13 funds opened new CERo Therapeutics positions in Q1 2022 and 3 closed out, a net change of +10 holders.
- The largest CERo Therapeutics buyer in Q1 2022 was Periscope Capital, an estimated $5.97M added.
- The largest CERo Therapeutics seller in Q1 2022 was Oaktree Capital Management, an estimated $1.98M sold.
Based on aggregated 13F filings for Q1 2022.